The UK's National Health Service is offering the 4CMenB vaccine, which provides cross-protection against gonorrhea, to patients at the greatest risk of infection.
Researchers in Italy observed a significant reduction in antibiotic use for sexually transmitted infections after the targeted introduction of doxyPEP.
Fifty-one babies were born with congenital chlamydia, and 23 were born with congenital syphilis.
A genomic analysis finds the percentage of US gonorrhea isolates carrying tetracycline resistance genes rose from 10% in 2020 to more than 30% in 2024.
Doxycycline post-exposure prophylaxis isn't formally available in the Netherlands, but 23% of respondents to an online survey said they've used it.
Drugmaker Innoviva said the FDA has accepted its new drug application for zoliflodacin, an investigational oral antibiotic for uncomplicated gonorrhea.
Starting in August, eligible patients can receive shots of 4CMenB, a vaccine for meningococcal B disease that provides moderate cross-protection against gonorrhea.
From 2016 to 2022, the rate of maternal syphilis in the US tripled.
A study at a sexual health clinic finds that significant declines in chlamydia and syphilis were sustained nearly 2 years after doxy-PEP was introduced.
Relative to unexposed children, those with congenital syphilis were at a 6-fold increased risk for first hospitalization, and those exposed to maternal syphilis were at nearly twice the risk.
